Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALKS

Alkermes plc

Nov 03 • 04:00PM ET

30.17

-0.53 -1.73 %

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR VTI IWM VB AVUV XBI VBK VXF SPSM FBT

Scroll to Statements

Index	RUT	P/E	14.93	EPS (ttm)	2.02	Insider Own	2.46%	Shs Outstand	165.10M	Perf Week	1.51%
Market Cap	4.98B	Forward P/E	18.26	EPS next Y	1.65	Insider Trans	-0.60%	Shs Float	161.05M	Perf Month	-2.87%
Enterprise Value	3.94B	PEG	-	EPS next Q	0.42	Inst Own	102.86%	Short Float	8.94%	Perf Quarter	13.42%
Income	338.83M	P/S	3.27	EPS this Y	-41.61%	Inst Trans	-1.52%	Short Ratio	7.23	Perf Half Y	-3.92%
Sales	1.52B	P/B	2.87	EPS next Y	-2.07%	ROA	15.08%	Short Interest	14.40M	Perf YTD	4.90%
Book/sh	10.50	P/C	4.48	EPS next 5Y	-24.01%	ROE	22.35%	52W High	36.45 -17.23%	Perf Year	14.67%
Cash/sh	6.73	P/FCF	10.15	EPS past 3/5Y	- -	ROIC	18.84%	52W Low	25.17 19.89%	Perf 3Y	42.72%
Dividend Est.	-	EV/EBITDA	10.14	Sales past 3/5Y	9.89% 5.87%	Gross Margin	85.66%	Volatility	4.98% 3.82%	Perf 5Y	103.99%
Dividend TTM	-	EV/Sales	2.59	EPS Y/Y TTM	3.40%	Oper. Margin	23.57%	ATR (14)	1.18	Perf 10Y	-46.52%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	1.08%	Profit Margin	22.27%	RSI (14)	48.35	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	3.67	EPS Q/Q	-11.21%	SMA20	-2.63%	Beta	0.49	Target Price	44.00
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	4.24%	SMA50	1.91%	Rel Volume	1.24	Prev Close	30.70
Employees	1800	LT Debt/Eq	0.04	Earnings	Oct 28 BMO	SMA200	-0.48%	Avg Volume	1.99M	Price	30.17
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.55% 10.45%	Trades		Volume	2,452,629	Change	-1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35

Show Previous Ratings

Oct-31-25 10:20AM	GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow (Zacks)
08:58AM	Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake (Zacks)
Oct-30-25 03:05PM	Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com)
10:32AM	BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View (Zacks)
10:28AM	BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales (Zacks)
01:45PM	Loading…
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
Oct-28-25 02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
11:00AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
08:20AM	Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:16AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-27-25 09:25AM	Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result (GuruFocus.com)
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:27AM	ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition (Zacks)
09:39AM	Loading…
09:39AM	LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls (The Fly)
05:25AM	Alkermes to acquire Avadel for $2.1bn (Pharmaceutical Technology)
Oct-22-25 04:11PM	Why Alkermes' $2.1 Billion Avadel Buyout Was 'Very Confusing' - At First (Investor's Business Daily)
07:36AM	Alkermes expands sleep portfolio with acquisition worth up to $2.1B (BioPharma Dive)
07:00AM	Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc (PR Newswire)
Oct-21-25 11:40AM	ALKS vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
09:55AM	Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Undervalued Right Now? (Zacks)
09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
Oct-20-25 04:00PM	Alkermes to Report Third Quarter Financial Results on October 28, 2025 (PR Newswire)
Oct-07-25 09:25AM	Do Options Traders Know Something About Alkermes Stock We Don't? (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 12:39PM	HC Wainwright Affirms Alkermes (ALKS) 'Neutral' Rating on Vibrance-1 Phase 2 Study (Insider Monkey)
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-12-25 09:00AM	Alkermes Appoints Joshua Reed as Chief Financial Officer (PR Newswire)
07:00AM	Loading…
Sep-11-25 07:00AM	Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards Program (PR Newswire)
Sep-10-25 11:30AM	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-08-25 05:19PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:12PM	Takeda and Alkermes share OX2R drug data for narcolepsy (Clinical Trials Arena)
03:15AM	Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 (PR Newswire)
Sep-03-25 11:30AM	Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 03:45AM	Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025 (Insider Monkey)
Aug-28-25 11:30AM	Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? (Zacks)
Aug-25-25 07:00AM	Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 (PR Newswire)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
Jul-31-25 01:01AM	ALKS- Positive Narcolepsy Drug Trial Puts this Biotech Name in Focus (MoneyShow) -5.16%
Jul-30-25 10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-29-25 09:30AM	Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:25AM	Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:21AM	Alkermes: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 10:36AM	CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? (Zacks)
09:23AM	Alkermes PLC (ALKS) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-23-25 10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
10:00AM	GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-22-25 10:00AM	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks)
Jul-21-25 06:29PM	Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia (Insider Monkey) -8.76%
04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:35PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
01:29PM	Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study (Benzinga)
06:22AM	Alkermes narcolepsy drug headed for late-stage testing (BioPharma Dive)
06:00AM	Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 (PR Newswire)
Jul-15-25 04:00PM	Alkermes to Report Second Quarter Financial Results on July 29, 2025 (PR Newswire)
09:47AM	DoorDash, Southwest downgraded: Wall Street's top analyst calls (The Fly)
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
09:55AM	How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% (Zacks)
Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jul-09-25 06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire)
Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 11:40AM	ALKS or CSLLY: Which Is the Better Value Stock Right Now? (Zacks)
Jun-18-25 09:51AM	Roku upgraded, Sarepta downgraded: Wall Streets top analyst calls (TipRanks)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-05-25 11:30AM	Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? (Zacks)
Jun-02-25 04:00PM	Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (PR Newswire)
07:00AM	Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences (PR Newswire)
May-29-25 07:00AM	Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 (PR Newswire)
May-19-25 08:00AM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
May-03-25 05:42PM	Alkermes plc (ALKS): Among Billionaire Jim Simons' RenTech's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-02-25 11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
03:01AM	Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... (GuruFocus.com)
May-01-25 04:31PM	Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (Seeking Alpha) +6.29%
11:21AM	Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:00AM	Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings (Zacks)
08:25AM	Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates (Zacks)
07:27AM	Alkermes: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports First Quarter 2025 Financial Results (PR Newswire)
Apr-30-25 10:58AM	Do Options Traders Know Something About Alkermes Stock We Don't? (Zacks)
07:00AM	New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) (PR Newswire)
Apr-29-25 10:01AM	Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-25 10:02AM	Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2025 (PR Newswire)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-02-25 04:00PM	Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
10:18AM	Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia (Clinical Trials Arena)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 07:00AM	Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia (PR Newswire)
Mar-27-25 07:00AM	New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder (PR Newswire)
Mar-25-25 12:44PM	Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Option Exercise	30.12	144,419	4,350,097	202,294	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Option Exercise	19.64	199,196	3,912,871	262,796	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Sale	32.78	204,921	6,718,278	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Sale	35.53	144,419	5,130,698	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	Officer	Feb 13 '25	Proposed Sale	35.53	144,419	5,130,694		Feb 13 04:36 PM
Hopkinson Craig C.	Officer	Feb 12 '25	Proposed Sale	32.78	204,921	6,718,276		Feb 12 04:19 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Option Exercise	22.22	97,632	2,169,137	145,208	Jan 31 08:42 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Sale	32.05	100,918	3,234,382	44,290	Jan 31 08:42 PM
Hopkinson Craig C.	Officer	Jan 30 '25	Proposed Sale	32.05	100,918	3,234,380		Jan 30 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Option Exercise	22.70	48,997	1,112,259	108,727	Dec 09 08:53 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 09 '24	Sale	32.07	61,151	1,961,406	47,576	Dec 09 08:53 PM
LAURENCIN CATO T	Director	Dec 09 '24	Option Exercise	22.52	2,691	60,601	25,704	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Sale	31.85	2,691	85,708	23,013	Dec 09 08:51 PM
LAURENCIN CATO T	Director	Dec 09 '24	Proposed Sale	31.85	2,691	85,708		Dec 09 05:27 PM
Hopkinson Craig C.	Officer	Dec 09 '24	Proposed Sale	32.07	61,151	1,961,404		Dec 09 05:24 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 05 '24	Sale	31.50	9,221	290,462	59,730	Dec 05 06:01 PM
Hopkinson Craig C.	Officer	Dec 05 '24	Proposed Sale	31.50	9,221	290,462		Dec 05 04:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 04 '24	Sale	30.77	14,349	441,550	68,951	Dec 04 04:52 PM
Hopkinson Craig C.	Officer	Dec 04 '24	Proposed Sale	30.77	14,349	441,550		Dec 04 04:19 PM
Nichols Christian Todd	Officer	Nov 27 '24	Proposed Sale	29.15	5,208	151,813		Nov 27 04:33 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Nov 27 '24	Sale	29.15	5,208	151,813	60,703	Nov 27 04:22 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Option Exercise	20.03	43,058	862,452	142,296	Nov 12 04:48 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 11 '24	Sale	30.08	58,996	1,774,576	83,300	Nov 12 04:48 PM
Hopkinson Craig C.	Officer	Nov 11 '24	Proposed Sale	30.08	58,996	1,774,578		Nov 12 04:15 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 06 '24	Sale	29.53	10,471	309,169	99,238	Nov 06 07:47 PM
Hopkinson Craig C.	Officer	Nov 06 '24	Proposed Sale	29.53	10,471	309,169		Nov 06 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience